Use of CA15‑3 for screening breast cancer: An antibody‑lectin sandwich assay for detecting glycosylation of CA15‑3 in sera
Authors:
Open Access
- 10 May 2018
- journal article
- research article
- Published by Spandidos Publications in Oncology Reports
- Vol. 40 (1) , 145-154
Abstract
Elevated serum CA15‑3 assessed by enzyme‑linked immunosorbent assay (ELISA) has been considered a diagnostic marker of breast cancer. However, accumulating data indicate that the current ELISA system for detecting CA15‑3, which targets the peptide backbone of CA15‑3, is not sufficiently sensitive to detect early or localized breast cancer. In the present study, we designed an antibody‑lectin sandwich assay detecting glycosylation of CA15‑3 in patients with breast cancer. Ιmmobilized anti‑CA15‑3 monoclonal antibody captures CA15‑3 in serum, and glycosylation of the CA15‑3 is detected with Concanavalin A (ConA) lectin, which preferentially bind high‑mannose N‑glycans. ConA provided the best signal for detecting serum CA15‑3 among 9 types of lectin, Since CA15‑3 is a heavily glycosylated protein, detecting the glycosylation of CA15‑3 should be a much more sensitive way to assess CA15‑3 than the current ELISA method. Linear responses were obtained in the anti‑CA15‑3 antibody‑ConA sandwich assay when sera were diluted up to 2000‑fold. This dilution factor is comparable with that of the current ELISA system which allows 50‑ to 100‑fold serum dilutions. The glycosylation level of CA15‑3 was found to increase with increasing breast cancer stage in the sandwich assay. The assay system appeared to efficiently discriminate breast cancer stage I (sensitivity: 63%, specificity: 69%), IIA (sensitivity: 77%, specificity: 75%), IIB (sensitivity: 69%, specificity: 86%) and III (sensitivity: 80%, specificity: 65%) from benign breast disease. The antibody‑lectin sandwich assay shows promise as a new prospect for the early detection of breast cancer.Keywords
This publication has 32 references indexed in Scilit:
- The sweet and sour of serological glycoprotein tumor biomarker quantificationBMC Medicine, 2013
- Protein Biomarkers for the Early Detection of Breast CancerInternational Journal of Proteomics, 2011
- Golgi GlycosylationCold Spring Harbor Perspectives in Biology, 2011
- High-Mannose Glycans are Elevated during Breast Cancer ProgressionMolecular & Cellular Proteomics, 2011
- CA 15-3: Uses and limitation as a biomarker for breast cancerClinica Chimica Acta, 2010
- Antibody-based enzyme-linked lectin assay (ABELLA) for the sialylated recombinant human erythropoietin present in culture supernatantJournal of Pharmaceutical and Biomedical Analysis, 2008
- A Minimal Fragment of MUC1 Mediates Growth of Cancer CellsPLOS ONE, 2008
- The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serumGlycobiology, 2008
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- History of lectins: from hemagglutinins to biological recognition moleculesGlycobiology, 2004